Regulation of ERBB3/HER3 Signaling in Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2014 Nov 18

PMID 25400118

Citations 58

Authors

Kalpana Mujoo

Byung-Kwon Choi

Zhao Huang

Ningyan Zhang

Zhiqiang An

Affiliations

Soon will be listed here.

Abstract

ERBB3/HER3 is emerging as a molecular target for various cancers. HER3 is overexpressed and activated in a number of cancer types under the conditions of acquired resistance to other HER family therapeutic interventions such as tyrosine kinase inhibitors and antibody therapies. Regulation of the HER3 expression and signaling involves numerous HER3 interacting proteins. These proteins include PI3K, Shc, and E3 ubiquitin ligases NEDD4 and Nrdp1. Furthermore, recent identification of a number of HER3 oncogenic mutations in colon and gastric cancers elucidate the role of HER3 in cancer development. Despite the strong evidence regarding the role of HER3 in cancer, the current understanding of the regulation of HER3 expression and activation requires additional research. Moreover, the lack of biomarkers for HER3-driven cancer poses a big challenge for the clinical development of HER3 targeting antibodies. Therefore, a better understanding of HER3 regulation should improve the strategies to therapeutically target HER3 for cancer therapy.

Citing Articles

Development of a novel anti-erythropoietin-producing hepatocellular receptor B6 monoclonal antibody EbMab-3 for flow cytometry.

Tanaka T, Kaneko Y, Yamamoto H, Li G, Fujisawa S, Satofuka H Biochem Biophys Rep. 2025; 41:101960.

PMID: 40065768 PMC: 11891606. DOI: 10.1016/j.bbrep.2025.101960.

Plasma-Activated Media Produced by a Microwave-Excited Atmospheric Pressure Plasma Jet Is Effective against Cisplatin-Resistant Human Bladder Cancer Cells In Vitro.

Jo A, Joh H, Bae J, Kim S, Chung J, Chung T Int J Mol Sci. 2024; 25(2).

PMID: 38279247 PMC: 10816804. DOI: 10.3390/ijms25021249.

AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.

Weng W, Meng T, Pu J, Ma L, Shen Y, Wang Z Mol Cancer Ther. 2023; 22(9):1013-1027.

PMID: 37302522 PMC: 10477830. DOI: 10.1158/1535-7163.MCT-23-0198.

Changes in HER3 expression profiles between primary and recurrent gynecological cancers.

Kojima Y, Sudo K, Yoshida H, Yazaki S, Tokura M, Mizoguchi C Cancer Cell Int. 2023; 23(1):18.

PMID: 36737733 PMC: 9898949. DOI: 10.1186/s12935-022-02844-z.

Glucocorticoid induced loss of oestrogen receptor alpha gene methylation and restoration of sensitivity to fulvestrant in triple negative breast cancer.

Intabli H, Gee J, Oesterreich S, Yeoman M, Allen M, Qattan A Gene. 2022; 851:147022.

PMID: 36347335 PMC: 11188041. DOI: 10.1016/j.gene.2022.147022.

References

Maspero E, Mari S, Valentini E, Musacchio A, Fish A, Pasqualato S . Structure of the HECT:ubiquitin complex and its role in ubiquitin chain elongation. EMBO Rep. 2011; 12(4):342-9. PMC: 3077247. DOI: 10.1038/embor.2011.21. View

Gyorffy B, Lage H . A Web-based data warehouse on gene expression in human malignant melanoma. J Invest Dermatol. 2006; 127(2):394-9. DOI: 10.1038/sj.jid.5700543. View

Rajkumar T, Stamp G, Hughes C, Gullick W . c-erbB3 protein expression in ovarian cancer. Clin Mol Pathol. 1996; 49(4):M199-202. PMC: 408058. DOI: 10.1136/mp.49.4.m199. View

Wiley H . Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res. 2003; 284(1):78-88. DOI: 10.1016/s0014-4827(03)00002-8. View

Carrion-Salip D, Panosa C, Menendez J, Puig T, Oliveras G, Pandiella A . Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol. 2012; 41(3):1128-38. DOI: 10.3892/ijo.2012.1509. View

Omerovic J, Santangelo L, Puggioni E, Marrocco J, DallArmi C, Palumbo C . The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation. FASEB J. 2007; 21(11):2849-62. DOI: 10.1096/fj.06-7925com. View

Abdullah J, Li X, Nachtman R, Jurecic R . FLRF, a novel evolutionarily conserved RING finger gene, is differentially expressed in mouse fetal and adult hematopoietic stem cells and progenitors. Blood Cells Mol Dis. 2001; 27(1):320-33. DOI: 10.1006/bcmd.2001.0390. View

Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R . Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995; 378(6555):390-4. DOI: 10.1038/378390a0. View

Olayioye M, Neve R, Lane H, Hynes N . The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. PMC: 313958. DOI: 10.1093/emboj/19.13.3159. View

10.

Hellwinkel O, Asong L, Rogmann J, Sultmann H, Wagner C, Schlomm T . Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma. Prostate Cancer Prostatic Dis. 2010; 14(1):38-45. DOI: 10.1038/pcan.2010.48. View

11.

Jackson-Fisher A, Bellinger G, Breindel J, Tavassoli F, Booth C, Duong J . ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Res. 2008; 10(6):R96. PMC: 2656891. DOI: 10.1186/bcr2198. View

12.

Garner A, Bialucha C, Sprague E, Garrett J, Sheng Q, Li S . An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013; 73(19):6024-35. PMC: 3924863. DOI: 10.1158/0008-5472.CAN-13-1198. View

13.

Hegde G, de la Cruz C, Chiu C, Alag N, Schaefer G, Crocker L . Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med. 2013; 5(171):171ra18. DOI: 10.1126/scitranslmed.3004438. View

14.

Tao J, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N . Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal. 2014; 7(318):ra29. PMC: 4283215. DOI: 10.1126/scisignal.2005125. View

15.

Schulze W, Deng L, Mann M . Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol. 2006; 1:2005.0008. PMC: 1681463. DOI: 10.1038/msb4100012. View

16.

Scott G, Goga A, Bhaumik D, Berger C, Sullivan C, Benz C . Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2006; 282(2):1479-86. DOI: 10.1074/jbc.M609383200. View

17.

Noto A, De Vitis C, Roscilli G, Fattore L, Malpicci D, Marra E . Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer. Oncotarget. 2013; 4(8):1253-65. PMC: 3787155. DOI: 10.18632/oncotarget.1141. View

18.

Lemoine N, Barnes D, Hollywood D, Hughes C, Smith P, Dublin E . Expression of the ERBB3 gene product in breast cancer. Br J Cancer. 1992; 66(6):1116-21. PMC: 1978009. DOI: 10.1038/bjc.1992.420. View

19.

Hynes N, Lane H . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-54. DOI: 10.1038/nrc1609. View

20.

Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J . An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 2010; 17(3):298-310. PMC: 2897158. DOI: 10.1016/j.ccr.2009.12.047. View